Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq

Retrovirology

Volumn 11, Issue 1, 2014, Pages

  Dudley, Dawn M ^a   Bailey, Adam L ^a   Mehta, Shruti H ^b   Hughes, Austin L ^c   Kirk, Gregory D ^b   Westergaard, Ryan P ^a   O'Connor, David H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antiretroviral therapy; Deep sequencing; Drug resistance genotyping; HIV drug resistance; Human immunodeficiency virus; Illumina MiSeq; Integrase inhibitor genotyping

Indexed keywords

INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; INTEGRASE; PRIMER DNA; RNA DIRECTED DNA POLYMERASE;

ADOLESCENT; ADULT; ANALYTICAL ERROR; APPLICATION SERVICE PROVIDER; ARTICLE; CHILD; CLADISTICS; CONTROLLED STUDY; DATA ANALYSIS; DATA ANALYSIS SOFTWARE; DRUG DATABASE; GENOTYPING TECHNIQUE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN HXB2); HUMAN IMMUNODEFICIENCY VIRUS 1 GROUP M; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE B; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE CRF01 AE; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE CRF02 AG; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE D; INFORMATION PROCESSING DEVICE; MACHINE LEARNING; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; NONHUMAN; STRUCTURAL GENE; TREATMENT FAILURE; VIRUS EXAMINATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; PROCEDURES; SENSITIVITY AND SPECIFICITY; VIROLOGY;

CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DNA PRIMERS; DRUG RESISTANCE, VIRAL; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV INTEGRASE; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 84924275201     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/s12977-014-0122-8     Document Type: Article

References (43)

1. Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S: Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, 381:2083-2090.
2. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, et al: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505.
3. van de Vijver DA, Nichols BE, Abbas UL, Boucher CA, Cambiano V, Eaton JW, Glaubius R, Lythgoe K, Mellors J, Phillips A, Sigaloff KC, Hallett TB: Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models. AIDS 2013, 27(18):2943-2951.
4. Abbas UL, Glaubius R, Mubayi A, Hood G, Mellors JW: Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa. J Infect Dis 2013, 208:224-234.
5. Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, Nachega JB, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriens J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S: Update on world health organization HIV drug resistance prevention and assessment strategy: 2004-2011. Clin Infect Dis 2012, 54(Suppl 4):S245-S249.
6. De Luca A, Hamers RL, Schapiro JM: Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. J Infect Dis 2013, 207(Suppl 2):S63-S69.
7. Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, Sauer MM, Kallas EG, O'Connor DH: Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 2012, 7:e36494.
8. DHHS: Recommendation on Integrase Inhibitor Use in Antiretroviral Treatment-Naive HIV-Infected Individuals from the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents; 2013.
9. Johnson LB, Saravolatz LD: The quad pill, a once-daily combination therapy for HIV infection. Clin Infect Dis 2014, 58:93-98.
10. Van den Eede P, Van Wesenbeeck L, Verlinden Y, Feyaerts M, Smits V, Verheyen A, Vanhooren L, Deloof A, Villacian J, Pattery T: HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance. Methods Mol Biol 2013, 1030:37-55.
11. Eshleman SH, Hudelson SE, Smith P, Hackett J, Holzmayer V, Swanson P, Devare SG, Marlowe N: Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses 2009, 25:343-345.
12. Eshleman SH, Hackett JJ, Swanson P, Cunningham SP, Drews B, Brennan C, Devare SG, Zekeng L, Kaptue L, Marlowe N: Performance of the Celera diagnostics ViroSeq HIV-1 genotyping system for sequence-based analysis of diverse human immunodeficiency virus type 1 strains. J Clin Microbiol 2004, 42:2711-2717.
13. Hemelaar J, Gouws E, Ghys PD, Osmanov S: Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS 2011, 25:679-689.
14. Aghokeng AF, Mpoudi-Ngole E, Chia JE, Edoul EM, Delaporte E, Peeters M: High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity. J Clin Microbiol 2011, 49:1635-1641.
15. Aitken SC, Kliphuis A, Wallis CL, Chu ML, Fillekes Q, Barth R, Stevens W, de Wit TF R, Schuurman R: Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes. J Clin Virol 2012, 54:21-25.
16. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, Nguyen DB, Bassey O, Ugbena R, Wadonda-Kabondo N, McConnell MS, Zulu I, Chilima B, Nkengasong J, Yang C: Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS One 2011, 6:e28184.
17. Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, Sanders E, Anzala O, Bekker LG, Stevens G, de Wit TF, Stevens W: Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1. J Virol Methods 2010, 163:505-508.
18. Acharya A, Vaniawala S, Shah P, Misra RN, Wani M, Mukhopadhyaya PN: Development, validation and clinical evaluation of a low cost in-house HIV-1 drug resistance genotyping assay for Indian patients. PLoS One 2014, 9:e105790.
19. Pou C, Noguera-Julian M, Perez-Alvarez S, Garcia F, Delgado R, Dalmau D, Alvarez-Tejado M, Gonzalez D, Sayada C, Chueca N, Pulido F, Ibanez L, Rodriguez C, Casadella M, Santos JR, Ruiz L, Clotet B, Paredes R: Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing. Clin Infect Dis 2014, 59:578-588.
20. Manasa J, Danaviah S, Pillay S, Padayachee P, Mthiyane H, Mkhize C, Lessells RJ, Seebregts C, de Wit TF, Viljoen J, Katzenstein D, De Oliveira T: An affordable HIV-1 drug resistance monitoring method for resource limited settings. J Vis Exp 2014, (85): doi: 10.3791/51242.
21. Simen BB, Braverman MS, Abbate I, Aerssens J, Bidet Y, Bouchez O, Gabriel C, Izopet J, Kessler HH, Stelzl E, Di Giallonardo F, Schlapbach R, Radonic A, Paredes R, Recordon-Pinson P, Sakwa J, St John EP, Schmitz-Agheguian GG, Metzner KJ, Daumer MP: An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. J Virol Methods 2014, 204:31-37.
22. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW: Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007, 17:1195-1201.
23. Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, Shi C, Eshleman JR, Guay LA, Jackson JB, Kumwenda N, Taha TE, Eshleman SH: Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006, 8:430-432.
24. Loman NJ, Misra RV, Dallman TJ, Constantinidou C, Gharbia SE, Wain J, Pallen MJ: Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012, 30:434-439.
25. Quail MA, Smith M, Coupland P, Otto TD, Harris SR, Connor TR, Bertoni A, Swerdlow HP, Gu Y: A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics 2012, 13:341.
26. Allhoff M, Schonhuth A, Martin M, Costa IG, Rahmann S, Marschall T: Discovering motifs that induce sequencing errors. BMC Bioinformatics 2013, 14(Suppl 5):S1.
27. Shao W, Boltz VF, Spindler JE, Kearney MF, Maldarelli F, Mellors JW, Stewart C, Volfovsky N, Levitsky A, Stephens RM, Coffin JM: Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology 2013, 10:18.
28. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD, Solomon L, Polk BF: The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991, 109:75-100.
29. Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH: Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis 2011, 53:725-731.
30. Gall A, Ferns B, Morris C, Watson S, Cotten M, Robinson M, Berry N, Pillay D, Kellam P: Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol 2012, 50:3838-3844.
31. Gibson RM, Meyer AM, Winner D, Archer J, Feyertag F, Ruiz-Mateos E, Leal M, Robertson DL, Schmotzer CL, Quinones-Mateu ME: Sensitive deep sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism. Antimicrob Agents Chemother 2014, 58(4):2167-2185.
32. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, Leitner T, Lundeberg J, Andersson B, Albert J: Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 2010, 5:e11345.
33. Bimber BN, Dudley DM, Lauck M, Becker EA, Chin EN, Lank SM, Grunenwald HL, Caruccio NC, Maffitt M, Wilson NA, Reed JS, Sosman JM, Tarosso LF, Sanabani S, Kallas EG, Hughes AL, O'Connor DH: Whole-genome characterization of human and simian immunodeficiency virus intrahost diversity by ultradeep pyrosequencing. J Virol 2010, 84:12087-12092.
34. Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, Chioma S, Moore RD, Siliciano RF: Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest 2013, 123:3848-3860.
35. Sutherland KA, Mbisa JL, Cane PA, Pillay D, Parry CM: Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. J Gen Virol 2014, 95:190-200.
36. Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Delfraissy JF, Rouzioux C, Chaix ML: Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. PLoS One 2011, 6:e24798.
37. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003, 31:298-303.
38. Shafer RW: Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006, 194(Suppl 1):S51-S58.
39. Administration USFaD: FDA allows marketing of four "next generation" gene sequencing devices. FDA news release, 2013. Department of Health and Human Services website: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm375742.htm .
40. Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD: Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS 2013, 27:2559-2566.
41. Salter ML, Lau B, Go VF, Mehta SH, Kirk GD: HIV infection, immune suppression, and uncontrolled viremia are associated with increased multimorbidity among aging injection drug users. Clin Infect Dis 2011, 53:1256-1264.
42. Vlahov D, Galai N, Safaeian M, Galea S, Kirk GD, Lucas GM, Sterling TR: Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol 2005, 161:999-1012.
43. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011, 28:2731-2739.